The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease

This study has been terminated.
(Patients recruitment and analysis were terminated)
Sponsor:
Information provided by (Responsible Party):
Ismail Kocyigit, TC Erciyes University
ClinicalTrials.gov Identifier:
NCT01589705
First received: April 30, 2012
Last updated: July 29, 2012
Last verified: July 2012
  Purpose

There are substantial data demonstrating increased endothelial dysfunction, inflammation and oxidative stress in patients with Autosomal dominant polycystic kidney disease (ADPKD), the association between serum uric acid level and endothelial dysfunction has not been elucidated yet in these patients. Therefore, in this study, the investigators aimed to examine the relationship between the uric acid level and the ED in normotensive ADPKD patients with preserved renal function.


Condition
Polycystic Kidney, Autosomal Dominant

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Endothelial Dysfunction in Patients With Polycystic Kidney Disease

Resource links provided by NLM:


Further study details as provided by TC Erciyes University:

Primary Outcome Measures:
  • Measurement of asymmetric dimethylarginine (ADMA) and flow mediated dilatation (FMD) [ Time Frame: 4 months ] [ Designated as safety issue: No ]
    ADMA,FMD and uric acid measurements were performed to determine endothelial dysfunction in ADPKD patients


Enrollment: 150
Study Start Date: January 2012
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
polycystic kidney ,no hypertension
The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function

Detailed Description:

This is the first study to evaluate the relationship between uric acid and endothelial dysfunction in patients with early stage ADPKD

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with early stage(preserved renal function) Autosomal dominant polycystic kidney disease (n = 91) from two academic medical center.We also excluded the patients with a previous diagnosis of hypertension, gout, diabetes, current use of oral antidiabetic medication, insulin, thiazide, allopurinol or uricosuric, or a fasting glucose level 126 mg/dl. In addition, the subjects with a history of smoking or current use of any anti-hypertensive medication and statins were excluded

Criteria

Inclusion Criteria:

  • ADPKD patients with normal renal function,
  • Normotensive ADPKD patients

Exclusion Criteria:

  • Patients with impaired kidney function,
  • Atherosclerotic disorders,
  • Diagnosis of hypertension, gout, diabetes,
  • Using of insulin, thiazide, allopurinol or uricosuric drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01589705

Locations
Turkey
Erciyes University Medical School
Kayseri, Turkey, 38039
Sponsors and Collaborators
TC Erciyes University
Investigators
Study Director: Bulent Tokgoz, Professor Erciyes University Medical School
  More Information

No publications provided by TC Erciyes University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ismail Kocyigit, TC Erciyes University Medical School, TC Erciyes University
ClinicalTrials.gov Identifier: NCT01589705     History of Changes
Other Study ID Numbers: Erciyes 2011/273
Study First Received: April 30, 2012
Last Updated: July 29, 2012
Health Authority: Sweden: Medical Products Agency

Keywords provided by TC Erciyes University:
Uric acid
polycystic kidney disease

Additional relevant MeSH terms:
Kidney Diseases
Polycystic Kidney Diseases
Multicystic Dysplastic Kidney
Polycystic Kidney, Autosomal Dominant
Urologic Diseases
Kidney Diseases, Cystic
Urogenital Abnormalities
Congenital Abnormalities
Uric Acid
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 01, 2014